吸入暴露引起的肺毒性和炎症的脂质媒介
Arjun Pitchai1, Kimberly Buhman2, Jonathan H Shannahan1
1School of Health Sciences, College of Health and Human Sciences, Purdue University, West Lafayette, IN, USA.
Inhalation toxicology
|February 29, 2024
概括
吸入暴露会破坏肺部生物活性脂质,导致炎症和疾病. 了解和准这些脂质通路为肺损伤提供了新的治疗策略.
科学领域:
- 肺部毒理学 肺部毒理学
- 脂质媒介生物学的生物学
- 炎症研究的研究.
背景情况:
- 吸入暴露经常导致肺炎,这是肺部疾病进展的关键驱动因素.
- 生物活性脂质是肺部炎症和溶解途径的关键调节者.
- 肺部生物活性脂质的失衡有助于毒性和疾病,如COPD和纳米粒子暴露所示.
研究的目的:
- 审查和整合最近关于吸入暴露对肺部生物活性脂质影响的发现.
- 突出关于肺损伤中的脂质介质的知识差距.
- 讨论检测脂质失调和潜在治疗策略的新兴方法.
主要方法:
- 对研究吸入暴露和肺脂质概况的文献综述.
- 整合有关促炎和解消脂质介质的数据.
- 讨论脂质量测量和治疗干预的分析技术.
主要成果:
- 吸入暴露,如香烟烟雾和银纳米颗粒,破坏了肺部生物活性脂质的平衡.
- 不调节的脂质有助于持续的炎症,肺损伤和疾病的发展.
- 技术进步使得这些脂质变化能够更好地识别和量化.
结论:
- 生物活性脂质是肺部对吸入侮辱的反应的核心.
- 准脂质代谢和信号通路为炎症性肺部疾病提供了一个有前途的治疗途径.
- 需要进一步的研究,以充分阐明脂质的作用和优化治疗方法.
相关概念视频
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
Drugs Used in Lower Respiratory Disorders: Overview
442
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
442
Antiasthma Drugs: Leukotriene Modifiers
298
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
298
Asthma: Pathogenesis and Management
396
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
396
Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Inhaled Medications
258
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
258


